KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Return on Capital Employed (2016 - 2026)

Teva Pharmaceutical Industries filings provide 18 years of Return on Capital Employed readings, the most recent being 8.52% for Q1 2026.

  • On a quarterly basis, Return on Capital Employed rose 696.0% to 8.52% in Q1 2026 year-over-year; TTM through Mar 2026 was 8.52%, a 696.0% increase, with the full-year FY2025 number at 8.11%, up 917.0% from a year prior.
  • Return on Capital Employed hit 8.52% in Q1 2026 for Teva Pharmaceutical Industries, up from 8.03% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 8.52% in Q1 2026 to a low of 6.72% in Q4 2022.
  • Median Return on Capital Employed over the past 5 years was 1.42% (2023), compared with a mean of 0.59%.
  • The widest YoY moves for Return on Capital Employed: up 1042bps in 2022, down -1140bps in 2022.
  • Teva Pharmaceutical Industries' Return on Capital Employed stood at 6.72% in 2022, then skyrocketed by 121bps to 1.42% in 2023, then crashed by -177bps to 1.09% in 2024, then surged by 835bps to 8.03% in 2025, then increased by 6bps to 8.52% in 2026.
  • The last three reported values for Return on Capital Employed were 8.52% (Q1 2026), 8.03% (Q4 2025), and 6.41% (Q3 2025) per Business Quant data.